ArticleThe journal of gene medicine2009
Targeted transduction of CD34+ hematopoietic progenitor cells in nonpurified human mobilized peripheral blood mononuclear cells.
Article in The journal of gene medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.Molecular therapy. Methods & clinical development · 2019Review
- Versatile targeting system for lentiviral vectors involving biotinylated targeting molecules.Virology · 2018Article
- Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell.Human gene therapy methods · 2013Article
- Article
- Library screening and receptor-directed targeting of gammaretroviral vectors.Future microbiology · 2013Review
- Single siRNA nanocapsules for enhanced RNAi delivery.Journal of the American Chemical Society · 2012Article
- Antibody-directed lentiviral gene transduction for live-cell monitoring and selection of human iPS and hES cells.PloS one · 2012Article
- Immunization delivered by lentiviral vectors for cancer and infectious diseases.Immunological reviews · 2011Review
- Antibody-directed lentiviral gene transduction in early immature hematopoietic progenitor cells.The journal of gene medicine · 2010Article
- Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins.Journal of virology · 2010Article
- Lentiviral vectors for immune cells targeting.Immunopharmacology and immunotoxicology · 2010Review
- Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.Retrovirology · 2010Article
- Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway.Journal of virology · 2009Article
- Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.Journal of acquired immune deficiency syndromes (1999) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundConventional gene-therapy applications of hematopoietic stem cells (HSCs) involve purification of CD34+ progenitor cells from the mobilized peripheral blood, ex vivo transduction of the gene of interest into them, and reinfusion of the transduced CD34+ progenitor cells into patients. Eliminating the process of purification would save labor, time and money, while enhancing HSCs viability, transplantability and pluripotency. Lentiviral vectors have been widely used in gene therapy because they infect both dividing and nondividing cells and provide sustained transgene expression. One of the exceptions to this rule is quiescent primary lymphocytes, in which reverse transcription of viral DNA is not completed.
methodsIn the present study, we tested the possibility of targeting CD34+ progenitor cells within nonpurified human mobilized peripheral blood mononuclear cells (mPBMCs) utilizing vesicular stomatitis virus G (VSV-G) pseudotyped lentiviral vectors, based on the assumption that the CD34+ progenitor cells would be preferentially transduced. To further enhance the specificity of vector transduction, we also examined utilizing a modified Sindbis virus envelope (2.2) pseudotyped lentiviral vector, developed in our laboratory, that allows targeted transduction to specific cell receptors via antibody recognition.
resultsBoth the VSV-G and 2.2 pseudotyped vectors achieved measurable results when they were used to target CD34+ progenitor cells in nonpurified mPBMCs.
conclusionsOverall, the data obtained demonstrate the potential of ex vivo targeting of CD34+ progenitor cells without purification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.